Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Liabilities and Shareholders Equity (2016 - 2025)

Marimed (MRMD) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $205.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 3.33% to $205.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $825.0 million, a 0.77% increase, with the full-year FY2024 number at $207.0 million, up 5.54% from a year prior.
  • Liabilities and Shareholders Equity was $205.6 million for Q3 2025 at Marimed, up from $204.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $212.7 million in Q3 2024 to a low of $90.0 million in Q1 2021.
  • A 5-year average of $169.1 million and a median of $189.4 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 63.2% in 2021, then decreased 3.33% in 2025.
  • Marimed's Liabilities and Shareholders Equity stood at $123.2 million in 2021, then increased by 23.54% to $152.2 million in 2022, then rose by 28.86% to $196.1 million in 2023, then increased by 5.54% to $207.0 million in 2024, then decreased by 0.67% to $205.6 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Liabilities and Shareholders Equity are $205.6 million (Q3 2025), $204.4 million (Q2 2025), and $208.0 million (Q1 2025).